A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology

被引:34
作者
Chen, Ming [1 ,2 ,3 ]
Jin, Ying [1 ,2 ,3 ]
Bi, Yalan [2 ]
Yin, Jie [1 ,2 ,3 ]
Wang, Yongxue [1 ,2 ,3 ]
Pan, Lingya [1 ,2 ,3 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Chinese Acad Med Sci, Dept Pathol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China
关键词
ovarian carcinoma; low-grade serous carcinoma; high-grade serous carcinoma; prognosis; NEOADJUVANT CHEMOTHERAPY; STAGE-II; CANCER; EXPRESSION; PACLITAXEL; HER-2/NEU; SYSTEM; MODEL;
D O I
10.2147/OTT.S67812
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Ovarian low-grade serous carcinoma (LGSC) and high-grade serous carcinoma have distinct molecular profiles, clinical behaviors, and treatment responses. The survival advantage for patients with low-grade carcinoma compared with patients with high-grade histology remains controversial. We retrospectively reviewed the medical charts of 381 patients with ovarian serous carcinoma at Peking Union Medical College Hospital from 2007 to 2010. Patients were classified into two groups according to MD Anderson two-tier system: 35 (9.2%) cases with LGSC and 346 with high-grade serous carcinoma. Patients with low-grade serous ovarian cancer had a significantly younger age at diagnosis (46 versus 56 years, P=0.046), and their median progression-free survival (PFS) and overall survival values were 35.0 and 54.0 months, respectively. A multivariate analysis showed that, for serous ovarian cancer, the histological grade was a significant prognostic factor for PFS but not for overall survival (P=0.022 and P=0.0566, respectively). When stratified by the existence of a residual disease, patients with low-grade disease who underwent cytoreductive surgery without macroscopic residual disease (>1 cm) had a significantly improved median PFS time (36.0 months) compared with that of patients with high-grade carcinoma who received optimal cytoreductive surgery (16.0 months, P=0.017). Conversely, patients with low-grade and high-grade carcinoma who were left with macroscopic residue (>1 cm) experienced a similarly shorter median PFS (10.0 and 13.0 months, respectively, P=0.871). The International Federation of Gynecology and Obstetrics stage and residual disease were significant prognostic factors of low-grade carcinoma, while positive ascites was associated with a worse PFS value. Our data showed that LGSC is a different entity from high-grade carcinoma and that LGSC was associated with improved PFS after optimal cytoreductive surgery but not suboptimal operation.
引用
收藏
页码:1891 / 1899
页数:9
相关论文
共 36 条
[1]   Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research [J].
Ahmed, Nuzhat ;
Stenvers, Kaye L. .
FRONTIERS IN ONCOLOGY, 2013, 3
[2]   Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis: A Clinicopathologic Study of 32 Patients From a Population-based Tumor Registry [J].
Ali, Rola H. ;
Kalloger, Steve E. ;
Santos, Jennifer L. ;
Swenerton, Kenneth D. ;
Gilks, C. Blake .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2013, 32 (06) :529-535
[3]   Reclassification of serous ovarian carcinoma by a 2-tier system [J].
Bodurka, Diane C. ;
Deavers, Michael T. ;
Tian, Chunqiao ;
Sun, Charlotte C. ;
Malpica, Anais ;
Coleman, Robert L. ;
Lu, Karen H. ;
Sood, Anil K. ;
Birrer, Michael J. ;
Ozols, Robert ;
Baergen, Rebecca ;
Emerson, Robert E. ;
Steinhoff, Margaret ;
Behmaram, Behnaz ;
Rasty, Golnar ;
Gershenson, David M. .
CANCER, 2012, 118 (12) :3087-3094
[4]   Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review [J].
Borley, J. ;
Wilhelm-Benartzi, C. ;
Brown, R. ;
Ghaem-Maghami, S. .
BRITISH JOURNAL OF CANCER, 2012, 107 (07) :1069-1074
[5]   Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the 'Mario Negri' Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group [J].
Buda, A ;
Floriani, I ;
Rossi, R ;
Colombo, N ;
Torri, V ;
Conte, PF ;
Fossati, R ;
Ravalioli, A ;
Mangioni, C .
BRITISH JOURNAL OF CANCER, 2004, 90 (11) :2112-2117
[6]  
Carlson Joseph, 2008, Diagn Histopathol (Oxf), V14, P352, DOI 10.1016/j.mpdhp.2008.06.009
[7]   Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer [J].
Chi, Dennis S. ;
Schwartz, Peter. E. .
GYNECOLOGIC ONCOLOGY, 2008, 111 (03) :391-399
[8]   The distal fallopian tube: a new model for pelvic serous carcinogenesis [J].
Crum, Christopher P. ;
Drapkin, Ronny ;
Miron, Alexander ;
Ince, Tan A. ;
Muto, Michael ;
Kindelberger, David W. ;
Lee, Yonghee .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2007, 19 (01) :3-9
[9]   Ovarian low-grade serous carcinoma: A comprehensive update [J].
Diaz-Padilla, Ivan ;
Malpica, Anais L. ;
Minig, Lucas ;
Chiva, Luis M. ;
Gershenson, David M. ;
Gonzalez-Martin, Antonio .
GYNECOLOGIC ONCOLOGY, 2012, 126 (02) :279-285
[10]   Survival in Women With Grade 1 Serous Ovarian Carcinoma [J].
Fader, Amanda Nickles ;
Java, James ;
Ueda, Stefanie ;
Bristow, Robert E. ;
Armstrong, Deborah K. ;
Bookman, Michael A. ;
Gershenson, David M. .
OBSTETRICS AND GYNECOLOGY, 2013, 122 (02) :225-232